Table 2.
Proportions of surviving and deceased COVID-19 patients according to tertiles of selected complete blood count parameters and biochemical variables.
| Total | Survived | Deceased | p | |
|---|---|---|---|---|
| n = 641 | n = 421 | n = 220 | ||
| Hemoglobin, n (%) | 0.198 | |||
| 1 (6.9–10.8) | 215 (33.5%) | 148 (35.2%) | 67 (30.5%) | |
| 2 (10.9–12.5) | 216 (33.7%) | 145 (34.4%) | 71 (32.3%) | |
| 3 (12.6–18.9) | 210 (32.8%) | 128 (30.4%) | 82 (37.3%) | |
| % Neutrophils, n (%) | < 0.001 | |||
| 1 (29.0–73.7) | 215 (33.5%) | 189 (44.9%) | 26 (11.8%) | |
| 2 (73.8–85.4) | 214 (33.4%) | 153 (36.3%) | 61 (27.7%) | |
| 3 (85.5–97.8) | 212 (33.1%) | 79 (18.8%) | 133 (60.5%) | |
| # Neutrophils, n (%) | < 0.001 | |||
| 1 (0.57–4.82) | 214 (33.4%) | 162 (38.5%) | 52 (23.6%) | |
| 2 (4.85–7.95) | 214 (33.4%) | 160 (38.0%) | 54 (24.6%) | |
| 3 (7.98–46.60) | 213 (33.2%) | 99 (23.5%) | 114 (51.8%) | |
| % Lymphocytes, n (%) | < 0.001 | |||
| 1 (0.7–8.9) | 216 (33.7%) | 84 (20%) | 132 (60%) | |
| 2 (9.0–17.5) | 213 (33.2%) | 156 (37.1%) | 57 (25.9%) | |
| 3 (17.6–54.9) | 212 (33.1%) | 181 (43%) | 31 (14.1%) | |
| # Lymphocytes, n (%) | < 0.001 | |||
| 1 (0.12–0.77) | 217 (33.9%) | 102 (24.2%) | 115 (52.3%) | |
| 2 (0.78–1.26) | 211 (32.9%) | 147 (34.9%) | 64 (29.1%) | |
| 3 (1.27–12.99) | 213 (33.2%) | 172 (40.9%) | 41 (18.6%) | |
| % Eosinophils, n (%) | < 0.001 | |||
| 1 (0–0.09) | 255 (39.8%) | 124 (29.5%) | 131 (59.5%) | |
| 2 (0.1–0.5) | 184 (28.7%) | 121 (28.7%) | 63 (28.6%) | |
| 3 (0.6–11.1) | 202 (31.5%) | 176 (41.8%) | 26 (11.8%) | |
| # Eosinophils, n (%) | < 0.001 | |||
| 1 (0.00) | 247 (38.5%) | 108 (25.6%) | 139 (63.2%) | |
| 2 (0.01–0.05) | 194 (30.3%) | 414 (33.5%) | 53 (24.1%) | |
| 3 (0.06–0.71) | 200 (31.2%) | 172 (40.9%) | 28 (12.7%) | |
| % Basophils, n (%) | 0.004 | |||
| 1 (0.0–0.1) | 363 (56.6%) | 221 (52.5%) | 142 (64.5%) | |
| 2 (0.2) | 146 (22.8%) | 99 (23.5%) | 47 (21.4%) | |
| 3 (0.3–2.3) | 132 (20.6%) | 101 (24%) | 31 (14.1%) | |
| # Basophils, n (%) | 0.023 | |||
| 1 (0.00–0.01) | 416 (64.9%) | 280 (66.5%) | 136 (61.8%) | |
| 2 (0.02) | 121 (18.9%) | 67 (15.9%) | 54 (24.6%) | |
| 3 (0.03–0.29) | 104 (16.2%) | 74 (17.6%) | 30 (13.6%) | |
| D-dimer, n (%) | 0.019 | |||
| 1 (190–830) | 172 (33.5%) | 129 (35.6%) | 43 (28.5%) | |
| 2 (840–1930) | 170 (33.1%) | 126 (34.8%) | 44 (29.1%) | |
| 3 (1940–35000) | 171 (33.3%) | 107 (29.6%) | 64 (42.4%) | |
| eGFR, n (%) | < 0.001 | |||
| 1 (3–51) | 216 (33.7%) | 98 (23.3%) | 118 (53.6%) | |
| 2 (52–80) | 213 (33.2%) | 154 (36.6%) | 59 (26.8%) | |
| 3 (81–90) | 212 (33.1%) | 169 (40.1%) | 43 (19.5%) | |
| Glycaemia, n (%) | 0.004 | |||
| 1 (39–95) | 161 (33.6%) | 119 (37.3%) | 42 (26.3%) | |
| 2 (96–128) | 163 (34%) | 112 (35.1%) | 51 (31.9%) | |
| 3 (129–880) | 155 (32.4%) | 88 (27.6%) | 67 (41.9%) | |
| Sodium, n (%) | < 0.001 | |||
| 1 (115–138) | 261 (40.7%) | 192 (45.6%) | 69 (31.4%) | |
| 2 (139–142) | 190 (29.6%) | 148 (35.2%) | 42 (19.1%) | |
| 3 (143–173) | 190 (29.6%) | 81 (19.2%) | 109 (49.5%) | |
| Potassium, n (%) | 0.017 | |||
| 1 (2.0–3.9) | 220 (34.3%) | 138 (32.8%) | 82 (37.3%) | |
| 2 (4.0–4.5) | 231 (36%) | 168 (39.9%) | 63 (28.6%) | |
| 3 (4.6–7.9) | 190 (29.6%) | 115 (27.3%) | 75 (34.1%) | |
| NT-proBNP, n (%) | < 0.001 | |||
| 1 (14–796) | 166 (33.5%) | 144 (40.7%) | 22 (15.5%) | |
| 2 (798–2579) | 165 (33.3%) | 120 (33.9%) | 45 (31.7%) | |
| 3 (2580–70000) | 165 (33.3%) | 90 (25.4%) | 75 (52.8%) | |
| CRP, n (%) | < 0.001 | |||
| 1 (0.1–2.1) | 210 (33.3%) | 175 (42%) | 35 (16.4%) | |
| 2 (2.2–7.1) | 210 (33.3%) | 146 (35%) | 64 (30%) | |
| 3 (7.2–34.6) | 210 (33.3%) | 96 (23%) | 114 (53.5%) | |
| PCT, n (%) | < 0.001 | |||
| 1 (0.05) | 215 (40.2%) | 187 (51.5%) | 28 (16.3%) | |
| 2 (0.06–0.19) | 147 (27.5%) | 103 (28.4%) | 44 (25.6%) | |
| 3 (0.20–189.55) | 173 (32.3%) | 73 (20.1%) | 100 (58.1%) | |
| IL-6, n (%) | < 0.001 | |||
| 1 (1.5–20.5) | 129 (33.5%) | 106 (37.6%) | 23 (22.3%) | |
| 2 (20.6–57.5) | 128 (33.2%) | 99 (35.1%) | 29 (28.2%) | |
| 3 (57.9–804.2) | 128 (33.2%) | 77 (27.3%) | 51 (49.5%) | |
| Ferritin, n (%) | 0.011 | |||
| 1 (15–397) | 161 (33.4%) | 124 (35.3%) | 37 (28.2%) | |
| 2 (403–804) | 162 (33.6%) | 125 (35.6%) | 37 (28.2%) | |
| 3 (805–7514) | 159 (33%) | 102 (29.1%) | 57 (43.5%) | |
| NLR, n (%) | < 0.001 | |||
| 1 (0.43–4.22) | 214 (33.4%) | 178 (42.3%) | 36 (16.4%) | |
| 2 (4.25–9.23) | 214 (33.4%) | 161 (38.2%) | 53 (24.1%) | |
| 3 (9.27–73.10) | 213 (33.2%) | 82 (19.5%) | 131 (59.5%) | |
| dNLR, n (%) | < 0.001 | |||
| 1 (−605 to 1.31) | 214 (33.4%) | 140 (33.2%) | 74 (33.8%) | |
| 2 (1.32–3.64) | 213 (33.3%) | 170 (40.4%) | 43 (19.6%) | |
| 3 (3.68–274) | 213 (33.3%) | 111 (26.4%) | 102 (46.6%) | |
| PLR, n (%) | < 0.001 | |||
| 1 (4.56–165.79) | 214 (33.4%) | 154 (36.6%) | 60 (27.3%) | |
| 2 (165.83–294.23) | 214 (33.4%) | 154 (36.6%) | 60 (27.3%) | |
| 3 (296.12–1660.00) | 213 (33.2%) | 113 (26.8%) | 100 (45.4%) | |
| LMR, n (%) | < 0.001 | |||
| 1 (0.26–1.63) | 215 (33.5%) | 103 (24.5%) | 112 (50.9%) | |
| 2 (1.64–2.84) | 213 (33.2%) | 161 (38.2%) | 52 (23.6%) | |
| 3 (2.85–38.21) | 213 (33.2%) | 157 (37.3%) | 56 (25.5%) |
Note, #, absolute count; eGFR, estimated Glomerular Filtration Rate; CRP, C Reactive Protein; CT, procalcitonin; IL-6, interleukin-6; NLR, neutrophil- to-lymphocyte ratio; dNLR, derived NLR ratio (neutrophil count divided by the result of WBC count minus neutrophil count); PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio. In bold significant variables.